Settlement secures $35-per-month insulin for all Minnesotans
A settlement with drug-maker Novo Nordisk resolves the state's years-long litigation over insulin pricing and follows similar settlements already reached with Eli Lilly and Sanofi.
'In 2018, when our lawsuit was filed, it could cost hundreds of dollars for Minnesotans to fill their insulin prescription," Ellison stated. "As of today, it will cost just $35."
The $35 per month price is available to all Minnesotans purchasing insulin from any of the three biggest manufacturers.
Even Minnesotans with insurance can choose to not use their insurance and pay no more than $35 per month, according to Ellison.
Additionally, Novo Nordisk has committed to continuing its Patient Assistance Program that provides free insulin to Minnesotans with an annual household income of less than or equal to 400% of the Federal Poverty Level, which is about $124,800 for a family of four.
Watch Monday's full announcement here:
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Eli Lilly to hike U.K. Mounjaro Price 170% after Trump push
Eli Lilly is raising the price of the weight loss drug Mounjaro in the U.K., after President Donald Trump ramped up pressure on drugmakers to lower U.S. prices and raise them abroad. The price of the drug is expected to rise by up to 170% in September, increasing the cost of a monthly supply at the highest dose from £122 ($165) to £330 ($447). The company said it had agreed with the British government to raise prices while 'maintaining access' for patients covered by the U.K.'s National Health Service. Last month, Trump wrote to 17 of the world's biggest drugmakers , including Eli Lilly, Novo Nordisk, and Pfizer, demanding they slash prices for U.S. consumers as part of his 'most favored nation' policy. The scheme aims to bring down drug prices by tying charges in the U.S. to lower ones abroad. Eli Lilly said Thursday that it has 'intensified efforts to align prices across developed countries, especially in Europe'. 'We are continuing to work with certain governments and expect to make any necessary pricing adjustments by September 1, while providing continued access for patients,' it said. Prescription drug prices in the U.S. are often two to three times higher on average than those in other developed nations, according to the nonprofit Commonwealth Fund. The list price for a month's supply of Mounjaro in the U.S. is $1,079.77 before insurance. Eli Lilly added that it supports Trump's goal of keeping the U.S. the 'world's leading destination for biopharmaceutical research and manufacturing, and the objective of more fairly sharing the costs of breakthrough medical research across developed countries.' 'This rebalancing may be difficult, but it means the prices for medicines paid by governments and health systems need to increase in other developed markets like Europe in order to make them lower in the US,' it said. Trump wrote in July that he would 'deploy every tool in our arsenal to protect American families from continued abusive drug pricing practices' if companies did not comply with his demands, saying other countries had been 'freeloading on U.S. innovation'. Meanwhile, the pharmaceutical industry is bracing for planned U.S. tariffs of medicines imported into the country. Eli Lilly said Thursday that it opposes the tariffs, saying they will raise costs and limit access to drugs. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
3 hours ago
- Yahoo
Ozempic creator Novo Nordisk will sell weight loss drugs for cheaper through this new partnership
Ozempic creator Novo Nordisk will sell weight loss drugs for cheaper through this new partnership originally appeared on TheStreet. Telemedicine company GoodRx () has been helping Americans find the cheapest way to buy drugs for years. Thanks to a new partnership with pharma giant Novo Nordisk () , the creator of Ozempic and Wegovy, it might soon be the cheapest way to buy branded weight loss drugs too. On Monday, the two firms announced a partnership which will allow patients with a prescription to get the branded medication for $499/mo, so long as they're willing to pay out of pocket and present the GoodRx coupon at their local pharmacy. At $499/mo the branded drug is only a little more expensive than compounded GLP-1 injectables sold by telehealth pharmacies, which have drawn the ire of pharmaceutical giants and the Food and Drug Administration (FDA). It's also more expensive than the $349/mo single-dose vial of Zepbound, the competing GLP-1 drug sold by competitor Eli Lilly () , which is also available through GoodRx. However, Ozempic and Wegovy's patented pens might be reason enough to pay up, since they're easier to use. Still, those with insurance might be eligible to have the cost completely covered, rather than pay the out of pocket cost. For that, patients should check with their prescriber and insurer. This is not Novo's first ride on the direct-to-consumer wagon. In April, it partnered with Hims & Hers HIMS (-1%) to help them sell Wegovy directly to customers. Novo ended that effort in July, alleging that the telehealth company intentionally undercut their branded medications through "deceptive promotion and selling of illegitimate, knockoff versions" of its drug, which "put patient safety at risk." A lawsuit has been filed against Hims & Hers. The failed "collaboration" between the companies spurred the departure of its chief executive, as well as a reduction to the company's annual guidance ahead of its quarterly earnings. Worst of all, it say Novo Nordisk lose market share to competitor Eli Lilly, which represents over half of the GLP-1 market. Novo's leadership have indicated a desire to expand its direct-to-consumer offerings and cut prices, looking to undercut both branded and compounded GLP-1 drugs. Ozempic creator Novo Nordisk will sell weight loss drugs for cheaper through this new partnership first appeared on TheStreet on Aug 18, 2025 This story was originally reported by TheStreet on Aug 18, 2025, where it first appeared.
Yahoo
6 hours ago
- Yahoo
GoodRx Is Soaring on a Novo Nordisk Deal. Should You Buy GDRX Stock Here?
GoodRx (GDRX) shares soared nearly 50% on Monday after announcing a GLP-1 partnership with the Danish pharmaceutical behemoth Novo Nordisk (NVO). In a press release this morning, the Nasdaq-listed firm said 'all strengths of Ozempic and Wegovy pens are now available to eligible self-paying patients for $499-per-month through GoodRx.' More News from Barchart Trade the Warren Buffett Rally in UnitedHealth Stock With This High-Reward, Low-Risk Options Strategy Lyft Generates Huge FCF Margins - LYFT Stock Is Too Cheap Cathie Wood Is Buying BLSH Stock After the Bullish IPO. Should You? Our exclusive Barchart Brief newsletter is your FREE midday guide to what's moving stocks, sectors, and investor sentiment - delivered right when you need the info most. Subscribe today! GoodRx stock has slightly outperformed in 2025, up just over 12% in the year to date. How Novo Deal May Help GoodRx Stock Teaming up with Novo Nordisk is a major win for GDRX shares because it positions the healthcare platform at the center of the booming GLP-1 weight-loss and diabetes drug market. Offering Ozempic and Wegovy at a flat $499 per month to self-paying customers helps GoodRx expand access to high-demand medications while reinforcing its value proposition as a cost-saving platform. Over time, this could drive user growth, boost engagement, and attract new pharmacy and pharma partnerships as well. In short, with GLP-1 drugs making headlines and consumer interest soaring, GoodRx stock is now tied to one of the most lucrative trends in healthcare. Why BofA Remains Bearish on GDRX Shares Despite the aforementioned positives, Bank of America analyst Allen Lutz says the Novo Nordisk deal is far from a sufficient reason to load up on GoodRx shares at current levels. In a note to clients, Lutz argued widespread pharmacy closures and changing reimbursement policy could make it difficult for GDRX stock to retain momentum in the days ahead. On Monday, the BofA analyst maintained his 'Underperform' rating and $3.40 price target on the healthcare platform, indicating potential downside of more than 30% from here. Wall Street Disagrees with BofA on GoodRx Investors should note, however, that Bank of America Securities is among the more bearish Wall Street firms on GoodRx stock in 2025. According to Barchart, the consensus rating on GDRX shares remains at 'Moderate Buy' with the mean target of $5.49 indicating potential 'upside' of another 5% from current levels. On the date of publication, Wajeeh Khan did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
